Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

b833c16261c663e95d4692b1484e6fbc.X0IppzKnfTNL7e4f2do6oxCQ0ntGxI2w6YMKz-oW0xw.LnV__gPICmEjmK9o6OlW-1L4lil1r-mCqMEyp4hs53AIGH2eUNUpUiidrw~7b82f029a8398b60082f8ef01bb0bcc5
20/08 Canaccord Genuity Initiates Incyte at Buy With $152 Price Target MT
17/08 Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating MT
13/08 Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating MT
03/08 Mizuho Adjusts Price Target on Incyte to $137 From $121 MT
03/08 Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating MT
31/07 Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating MT
30/07 JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating MT
29/07 Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says MT
29/07 TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating MT
29/07 Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating MT
29/07 Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating MT
29/07 BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating MT
29/07 Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating MT
29/07 Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating MT
29/07 HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating MT
29/07 Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating MT
29/07 RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating MT
28/07 Oppenheimer Raises Incyte Price Target to $120 From $107 MT
28/07 Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept MT
28/07 Wells Fargo Adjusts Price Target on Incyte to $116 From $101 MT
23/07 JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating MT
22/07 Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating MT
20/07 Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating MT
15/07 BofA Securities Raises Incyte Price Target to $136 From $124 MT
14/07 Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+0.82%
-34.19%
-5.9%
+24.18%
+27.29%
+7%
-2%
+20.39%
+5.96%
Average +4.84%
Weighted average by Cap. +2.26%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
128.12USD
Average target price
127.12USD
Spread / Average Target
-0.78%
High Price Target
155.00USD
Spread / Highest target
+20.98%
Low Price Target
86.00USD
Spread / Lowest Target
-32.88%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Canaccord Genuity
Piper Sandler
Bernstein
Mizuho Securities
Leerink Partners
Argus
JPMorgan Chase
Barclays
RBC Capital Markets
Goldman Sachs
HC Wainwright
Guggenheim
Jefferies & Co.
BMO Capital
Morgan Stanley
TD Cowen
Oppenheimer
Stifel Nicolaus
Wells Fargo Securities
BofA Securities
UBS
Truist Securities
William O'Neil & Co
Evercore ISI
Deutsche Bank Securities
Wolfe Research
Citigroup
William Blair & Co.
JMP Securities
SVB Securities LLC
Morningstar
Cowen
SVB Leerink
Benchmark Capital
Credit Suisse
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
128.12USD
Average target price
127.12USD
Spread / Average Target
-0.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
  4. I1NC34 Stock
  5. Consensus Incyte Corporation